Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Niagen Bioscience (NAGE) Operating Leases: 2019-2025

Historic Operating Leases for Niagen Bioscience (NAGE) over the last 7 years, with Sep 2025 value amounting to $3.1 million.

  • Niagen Bioscience's Operating Leases rose 6.90% to $3.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.1 million, marking a year-over-year increase of 6.90%. This contributed to the annual value of $2.6 million for FY2024, which is 21.21% down from last year.
  • Per Niagen Bioscience's latest filing, its Operating Leases stood at $3.1 million for Q3 2025, which was down 6.06% from $3.3 million recorded in Q2 2025.
  • Over the past 5 years, Niagen Bioscience's Operating Leases peaked at $4.7 million during Q4 2021, and registered a low of $1.4 million during Q1 2021.
  • For the 3-year period, Niagen Bioscience's Operating Leases averaged around $3.3 million, with its median value being $3.3 million (2025).
  • As far as peak fluctuations go, Niagen Bioscience's Operating Leases surged by 224.23% in 2022, and later declined by 23.68% in 2024.
  • Niagen Bioscience's Operating Leases (Quarterly) stood at $4.7 million in 2021, then decreased by 10.64% to $4.2 million in 2022, then decreased by 21.43% to $3.3 million in 2023, then fell by 21.21% to $2.6 million in 2024, then increased by 6.90% to $3.1 million in 2025.
  • Its Operating Leases was $3.1 million in Q3 2025, compared to $3.3 million in Q2 2025 and $3.5 million in Q1 2025.